3003

Hangzhou Tigermed Consulting

300347.SHE tigermedgrp.com + Research + Basket
ISIN CNE100001KV8
Employees 11,130
Phone 86 571 2888 7227
Fiscal year end December
IPO Aug 17, 2012
Address No. 508, Lujiatan Street, Hangzhou, China, 310051
51.61
-2.26 (-4.20%)
CNY · SHE
52-week range
35.47
67.65
Trading at 50% of the 52-week range
Market Cap
44.13B
P/E Ratio
0.00
Forward P/E
28.99
Book Value
23.69
Div. Yield
0.23%
% Institutions
31.85%
% Insiders
32.53%

1 Year

-11.8%

3 Year

-25.6%

10 Year

+169.8%
Description

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

Actions

Add an action for 300347.SHE, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Xiaoping Ye D.Phil, EMBA, M.D., Ph.D. Co-Founder & Chairman 1963
Mr. Zengyu Wen President, GM & Executive Director 1980
Mr. Hao Wu Co- President 1967
Dr. Xiaochun Cao M.D. Co-Founder & Executive Director 1969
Ms. Chengcheng Yang SVP & CFO 1974
Ms. Xiao Ri Li Secretary 1983
Mr. Yifei Peng Senior VP & COO NA
Dr. Tianrong Ji M.D., Ph.D. SVP & Chief Investment Officer NA
Xiao Cui Chen Accounting Supervisor NA
Mr. Song Meng VP & Chief Technology Officer NA

Financial Highlights

▼
Market Cap: $44.13B
EBITDA: $950.16M
PEG Ratio: $0.00
Book Value: $23.69
Dividend/Share: $0.13
Dividend Yield: 0.23%
Earnings/Share: $-0.47
Profit Margin: -5.33%
Operating Margin: 12.62%
ROA (TTM): 1.62%
ROE (TTM): -1.71%
Revenue (TTM): $7.60B
Revenue/Share (TTM): $8.94
Earnings Growth (YOY): -76.80%
Revenue Growth (YOY): 17.40%

Valuation Metrics

Enterprise Value: $41.97B
Trailing P/E: 0.00
Forward P/E: 28.99

Shares Statistics

Shares Outstanding: 732.02M
Shares Float: 592.32M
% Insiders: 32.53%
% Institutions: 31.85%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$6.83B
Cost of Goods Sold
adjust
$-4.96B
Gross Profit
subtotal
$1.87B
SG&A
adjust
$-322.20M
R&D
adjust
$-257.64M
Other Operating Expense
adjust
$-5.59B
Operating Income
subtotal
$666.64M
Other / Non-Operating Items
adjust
$221.25M
Net Income
subtotal
$887.89M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about 300347.SHE!